



**ASX RELEASE**

21 August 2012

**QRxPharma CEO discusses Productive Meeting with FDA  
regarding MOXDUO<sup>®</sup> NDA on Open Briefing**

**Sydney, Australia and Bedminster, New Jersey** – QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) announced yesterday the United States Food and Drug Administration (FDA) clarified to Company representatives during a post submission review meeting the steps required for approval of immediate release MOXDUO.

An audio broadcast recorded today with Dr. John Holaday, Managing Director and Chief Executive Officer and Dr. Edward Rudnic, Chief Operating Officer of QRxPharma discussing this productive meeting held with the FDA regarding MOXDUO NDA is available on Open Briefing.

*To listen*, copy the following details into your web browser: [www.openbriefing.com](http://www.openbriefing.com) and click on the QRxPharma icon.

###

For more information please contact:

John W Holaday, Ph.D.  
Managing Director and Chief Executive Officer  
Tel: +1 301 908 3086  
Email: [john.holaday@qrxpharma.com](mailto:john.holaday@qrxpharma.com)

Chris J Campbell  
Chief Financial Officer and Company Secretary  
Tel: +61 2 9492 8021  
Email: [chris.campbell@qrxpharma.com](mailto:chris.campbell@qrxpharma.com)

### **About QRxPharma**

QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) is a commercial-stage specialty pharmaceutical company focused on the development and commercialisation of new treatments for pain management. Based on a development strategy that focuses on enhancing and expanding the clinical utility of currently marketed compounds, the Company's product portfolio includes both late and early stage clinical drug candidates with the potential for reduced risk, abbreviated development paths, and improved patient outcomes. QRxPharma entered into a strategic collaboration with Actavis Inc. in December 2011 for the commercialisation of MOXDUO<sup>®</sup> in the US acute pain market. Additionally, the Company's clinical pipeline includes an intravenous (IV) and continuous release (CR) formulation of MOXDUO<sup>®</sup>. For more information, visit [www.qrxpharma.com](http://www.qrxpharma.com).

### **Forward Looking Statements**

This release contains forward-looking statements. Forward-looking statements are statements that are not historical facts; they include statements about our beliefs and expectations. Any statement in this release that states our intentions, beliefs, expectations or predictions (and the assumptions underlying them) is a forward-looking statement. These statements are based on plans, estimates and projections as they are currently available to the management of QRxPharma. Forward-looking statements therefore speak only as of the date they are made, and we undertake no obligation to update publicly any of them in light of new information or future events. By their very nature, forward-looking statements involve risks and uncertainties. A number of important factors could therefore cause actual results to differ materially from those contained in any forward-looking statement. Such factors include risks relating to the stage of products under development; uncertainties relating to clinical trials; dependence on third parties; future capital needs; and risks relating to the commercialisation of the Company's proposed products.